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Abbreviations:  
LIGHT: homologous to lymphotoxin, exhibits inducible expression and competes with 
HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on 
T lymphocytes (also known as HVEM-L, TNFSF14, CD258);  
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HVEM: Herpesvirus entry mediator (TR2, HveA, TNFRSF14, CD270);  
BTLA: B-and T lymphocyte attenuator (CD272) 
LTbR: Lymphotoxin beta receptor 
TCR: T cell receptor 
TNF: Tumor necrosis factor  
TNFSF: Tumor necrosis factor superfamily  
TNFRSF: Tumor necrosis factor receptor superfamily 
HSV1: Herpes simplex virus 1  
NK: Natural killer cells 
SALM5: Synaptic adhesion-like molecule 5 
IFN: Interferon 
ITIM: Immune receptor tyrosine inhibitory motif 
NF-kB: Nuclear factor kappa B 
SHP1/2: Src homology domain 2 (SH-2) containing protein tyrosine phosphatases 
EAE: Experimentally-induced hepatitis  
ConA: Concanavalin A 
WT: Wild type  
KO: knock-out  
CLL: Chronic lymphocytic leukemia 
PI3K: Phosphoinositide 3-kinase 
AKT: Protein kinase B (PKB), also known as Akt, is a serine/threonine-specific protein 
kinase 
TRAF2: TNF receptor-associated factor 2 
MAPK: Mitogen-activated protein kinases 
3 
 
Correspondence letter  
Temporal and spatial expression of cosignaling receptors and their ligands regulates the 
early stages of T-cell activation (signal 1, T-cell receptor (TCR) signaling and signal 2, 
costimulation/coinhibition), clonal expansion and T-cell survival during their 
differentiation towards effector T cells. Once the inflammatory stimulus is eliminated, 
effector T cells return to homeostasis after undergoing a contraction phase by activation-
induced cell death and the intervention of ligands for coinhibitory receptors, leaving a 
population of long-term memory T cells. The expression of ligands for coinhibitory 
receptors on hematopoietic cells and, more importantly, on non-hematopoietic cells of 
peripheral tissues is a key process in tuning the functional activity of effector T cells to 
prevent excess tissue inflammation that may lead to immunopathology and subsequent 
tissue dysfunction. 
Two groups of proteins of the immunoglobulin superfamily (IgSF), CTLA-
4/CD28/CD80/CD86 and PD-1/PD-L1/PD-L2, which function as cosignaling receptors 
and ligands, are the focus of intense research. The former group functions at the early 
phase of T-cell activation, and the latter group predominantly controls the effector phase 
of the immune response in peripheral tissues. In recent years, blockade of these immune 
checkpoints to potentiate effective antitumor responses has enormously advanced the 
field of cancer immu-notherapy.1 However, only a subgroup of patients responded to 
therapy with current immune checkpoint inhibitors. Therefore, other modulators of the T-
cell response need to be explored. 
Another area of recent intense research is the molecular switch HVEM (herpes virus entry 
mediator, TNFRSF14, CD270), a molecule broadly expressed in hematopoietic and non-
hematopoietic cells. HVEM was first identified as the receptor of herpes simplex virus 1 
(HSV-1), which binds via the viral gD protein. However, HVEM has other interaction 
partners that bind distinct HVEM sites; BTLA (B- and T-lymphocyte attenuator, CD272), 
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CD160 and gD compete for binding to the CRD1 and CRD2 domains of HVEM, whereas 
the TNF (tumor necrosis factor) family ligand LIGHT binds to HVEM at the CRD2 and 
CRD3 domains on the opposite side of the molecule. HVEM also binds to LTα (another 
member of the TNF superfamily) and to SALM 5, a molecule expressed on myeloid cells 
that regulates neuroinflammation. In addition to HVEM, LIGHT also binds to LTβR. A 
viral paralog of HVEM, UL144, can inhibit T cells via BTLA without activating natural 
killer (NK) cells expressing CD160.2 
BTLA is a receptor of IgSF and was first identified as an inhibitory receptor. BTLA is 
expressed at different levels on the cell membrane of most hematopoietic cells of 
lymphoid lineage. BTLA is expressed at high levels in B cells, at lower levels in CD4 T 
cells and at even lower levels in CD8 T cells. BTLA is also expressed in NK cells, NKT 
cells and myeloid cells.3,4 BTLA regulates the homeostasis of γδ T cells and innate 
lymphoid cells (ILCs), promotes the survival of effector T cells and contributes to their 
differentiation towards memory T cells.5 Within the myeloid lineage, BTLA in CD8α+ 
dendritic cells functions as an inhibitory receptor that regulates DC homeostasis in 
lymphoid tissues. Moreover, the binding of HVEM on T cells by BTLA expressed in 
CD8+DEC205+ dendritic cells can promote their differentiation towards peripheral Tregs 
through upregulation of CD5.6 
The main isoform of CD160 is a GPI (glycosylphosphatidyl inositol)-anchored molecule 
that was discovered by expression screening of a cDNA library from an NK tumor cell 
line using a monoclonal antibody, clone BY55. In addition to HVEM, CD160 also binds 
with low affinity to classical and non-classical MHC class I, competing with CD8 for 
binding to the alpha 3 domain of MHC class I (Fig. 1, upper panel).7 CD160 expression 
is mainly, but not uniquely, restricted to cytotoxic cells, such as NKT cells and NK cells, 
and CD160 is also present in T cells, such as TCRαβ+ and TCRγδ+ intraepithelial 
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lymphocytes of the intestine and a subset of memory CD8 T cells in mice and humans. 
HVEM activates CD160 in NK cells, promoting signal transduction through the ERK1/2 
and PI3K (phosphatidylinositol 3-kinase)–AKT (protein kinase B (PKB)) path-ways, 
leading to the production of IFNγ, whereas the binding of HVEM to CD160 in a subset 
of human CD4+ T cells delivers a coinhibitory signal. CD160 is also expressed in 
endothelial cells of newly formed blood vessels but not in endothelial cells of non-
inflamed tissues. CD160 is also present in malignant B cells in chronic lymphocytic 
leukemia patients but not in normal B cells. 
 
Cross-regulation and bidirectional signaling of the HVEM-LIGHT and HVEM-
BTLA-CD160 network  
The HVEM–LIGHT and HVEM–BTLA-CD160 network is a self-regulating 
ligand/receptor system that delivers bidirectional survival, proinflammatory and 
inhibitory signals to T cells, 
NKT cells and other immune cells. Under homeostatic (non-inflammatory) conditions, 
HVEM and BTLA interact in cis to provide an intrinsic inhibitory signal that modulates 
T-cell activation. Upon activation, T cells rapidly and transiently express membrane-
bound LIGHT, which binds to and internalizes HVEM. Disruption of the HVEM–BTLA 
complex leaves BTLA available to signal in trans through HVEM present in neighboring 
cells. Therefore, after T-cell activation and during the course of T-cell differentiation, the 
expression of HVEM decreases, while that of BTLA increases. This allows BTLA and 
transiently expressed LIGHT in activated T cells to interact with HVEM in trans in 
surrounding cells and deliver bidirectional costimulatory signals. Ligand-induced 
oligomerization of HVEM leads to the recruitment of TRAF2 (TNF receptor-associated 
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factor 2) and activation of downstream nuclear factor kappa B (NF-κB) in T cells and 
other immune cells (Fig. 1, middle panel).8 
The intracellular domain of BTLA contains immunoreceptor tyrosine-based inhibition 
motifs (ITIMs) that, once phosphorylated, can recruit Src homology domain 2 (SH2)-
containing protein tyrosine phosphatases (SHP-1 and SHP-2) to suppress antigen receptor 
signaling (Fig. 1, middle panel). Aged BTLA-deficient BALB/c mice are highly 
susceptible to spontaneous autoimmune hepatitis-like disease and to experimental 
autoimmune encephalitis (EAE) compared with their wild-type (WT) counterparts, 
suggesting a coinhibitory role of BTLA in T cells.4 CD160-deficient mice, however, 
show no alterations in lymphocyte development or cell numbers, although the control of 
NK-sensitive hematopoietic tumors (class I deficient cell line, RMA-S) is modestly 
compromised due to defective NK secretion of IFN-γ and the subsequent impairment of 
their effector function.9 
However, BTLA is more than an inhibitory receptor. Stimulation of BTLA by HVEM is 
required for T-cell survival. Indeed, the survival of donor BTLA-deficient T cells is 
impaired after T-cell activation in a setting of allogeneic bone marrow transplantation, 
and the conversion of naive T cells to effector and memory cells is also impaired in 
BTLA-deficient mice.10 
The interaction of HVEM with CD160 plays a role in the gut epithelium. Kronenberg's 
group, in a mouse model of adoptive transfer of pathogenic CD4+ CD45RBhigh T cells 
to Rag1-deficient mice, was the first to focus on this interaction. In this model, colitis was 
greatly accelerated and exacerbated in Rag1-HVEM double-deficient mice compared 
with control Rag1-deficient mice. HVEM-deficient mice were also more susceptible to 
intestinal bacterial infections than WT mice. CD160 expressed on innate-like 
intraepithelial lymphocytes can bind to HVEM on epithelial cells in the gut and transduce 
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proinflammatory signals, promoting the release of antimicrobial peptides that provide 
protection against infection (Fig. 1, lower panel). However, in the intestine, the HVEM–
LIGHT interaction appears to be less critical and of less relevance than the HVEM–
CD160 interaction. This less relevant interaction has also been described by Kronenberg's 
group in two acute models of colitis induced by either adoptive transfer of 
CD4+CD45RBhigh T cells into Rag1-deficient or LIGHT-Rag1 double-deficient 
recipient mice of by the administration of dextran sulfate sodium salt (DSS) to LIGHT-
deficient or wild-type C57BL/6J mice. In these experimental settings, LIGHT deficiency 
in neutrophils regulated inflammation of the colon via interacting with LTβR expressed 
on non-hematopoietic cells rather than via HVEM.11 
The HVEM–BTLA–CD160 signaling network inhibits NKT cells in a mouse model of 
concanavalin A (ConA)-induced hepatitis, an autoimmune-like disease mainly promoted 
by liver invariant NKT cells positive for FasL, although systemic activation of T cells 
also occurs. ConA-induced hepatitis in BTLA- or CD160-deficient mice is more 
aggressive than in WT mice, suggesting that BTLA and CD160 function as negative 
regulators of NKT cells. 12,13 In this same model, contrasting results have been reported 
in HVEM-deficient mice with either an increased or decreased liver pathology. One 
publication also showed increased susceptibility of HVEM-deficient mice to 
experimentally induced autoimmune encephalitis.14 
In the HVEM network, interactions between two superfamilies of molecules (TNFRSF–
TNFSF and immunoglobulin) occur, offering multiple targetable molecules for enhancing 
or attenuating immunological responses in immune-related diseases or cancer 
immunotherapy. Accordingly, anti-BTLA antibodies have shown effective antitumor 
activity in melanoma and mammary carcinoma models. Although HVEM has both 
stimulatory and inhibitory functions, the delivery of coinhibitory signals may be dominant 
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over proinflammatory signals. Thus, stimulating immune cells through LIGHT or NK 
cells through CD160 or relieving the inhibition imposed by HVEM and BTLA will be of 
great interest to enhance antitumor responses. 
The use of a soluble recombinant viral HVEM analog, UL144, that only binds to BTLA 
and not to CD160 or soluble mutated HVEM-engineered molecules lacking the 
costimulatory binding site for LIGHT would represent promising biologics for the 
attenuation of immune responses. 
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Legends to figures 
Figure 1: HVEM is a bidirectional molecular switch that transduces positive and 
negative signals.  
Upper panel: The soluble form of CD160 competes with CD8 for binding to the alpha 3 
domain of MHC class I, inhibiting the cytotoxic function of CD8 T cells. The CD160-
GPI isoform anchored to the cell membrane of NK cells can be enzymatically released 
by the functional activity of a metalloprotease. Although this soluble form of CD160 
binds with weak affinity to the alpha 3 domain of MHC class I, it can compete with the 
beta subunit of the CD8 T-cell coreceptor for binding at the same site, preventing this 
interaction and, consequently, inhibiting the cytotoxic functional activity of CD8 T 
cells.15  
Middle panel: HVEM is a bidirectional molecular switch that transduces positive and 
negative signals. As a receptor, HVEM can deliver proinflammatory and survival signals 
when engaged by BTLA or LIGHT. As a ligand, HVEM delivers coinhibitory signals 
through CD160 and BTLA in T cells and NKT cells, costimulatory signals to CD160-
positive NK cells or prosurvival signals to BTLA-expressing effector and memory T 
cells. BTLA and CD160 compete for the same binding site within the CRD1–CRD2 
region of HVEM, while LIGHT independently binds the opposite side of HVEM within 
the CRD2–CRD3 region. a. The cytoplasmic domain of BTLA contains three conserved 
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tyrosine-based signaling motifs, a proximal Grb-2 recognition consensus and two distal 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The membrane-proximal 
tyrosine within the YDND motif binds to Grb-2, which interacts with the p85 subunit of 
phosphatidylinositol 3-kinase (PI3K), activating the PI3K/AKT survival pathway. The 
binding of HVEM to BTLA in a cis configuration delivers intrinsic inhibitory signals to 
naive T cells and prevents HVEM from binding in trans to BTLA or CD160. The 
intracellular ITIM motifs of BTLA, once phosphorylated, recruit SHP1/2 (Src homology 
domain 2 (SH-2) containing protein tyrosine phosphatases) phosphatases to 
dephosphorylate and inhibit downstream signaling molecules of early T-cell activation. 
b. Soluble LIGHT proteolytically released from activated T-cells binds and stabilizes the 
HVEM/BTLA complex in the cis configuration without activating HVEM. c. Upon T-
cell activation, membrane-bound LIGHT is transiently expressed on T cells. Binding of 
LIGHT to the HVEM–BTLA complex on the same cell displaces BTLA and promotes 
HVEM internalization, which terminates negative signaling through BTLA and decreases 
the threshold of T-cell activation. Then, membrane-bound BTLA is available to interact 
in trans with HVEM expressed in surrounding T cells and other immune and non-immune 
cells. The binding of BTLA by HVEM can also deliver proinflammatory and prosurvival 
signals to T cells through activation of the survival PI3K–AKT signaling pathway. Trans 
interactions between LIGHT and HVEM result in bidirectional proinflammatory and 
survival signals in T cells. Lower panel: Bidirectional signaling upon HVEM–CD160 
interactions. a. Binding of HVEM in T cells by CD160 expressed on cytotoxic cells leads 
to NF-κB activation and the promotion of T-cell survival. b. The binding of HVEM in 
the intestinal epithelium by CD160 of gamma/delta T cells or innate lymphoid cells 
activates STAT-3, leading to the secretion of antimicrobial peptides that prevent 
infection. c. In vitro addition of soluble BTLA.Ig or soluble CD160.Ig to HVEM-
transfected HEK293T cells activates the nuclear factor kappa B (NF-κB) transcription 
factor and leads to the subsequent expression of proinflammatory genes. d. Binding of 
the GPI-anchored isoform of CD160 co-inhibits NKT cells and human CD4 T cells by an 
uncharacterized mechanism. e. The binding of CD160 in activated NK cells by HVEM 
increases their functional activity and the secretion of IFN-γ. f. HVEM delivers 
prosurvival signals to chronic lymphocytic leukemia (CLL) cells expressing CD160. 
 
 
 
11 
 
References  
1. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of 
B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing 
vaccines induces rejection of subcutaneous and metastatic tumors accompanied 
by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999). 
2. Bossen, C. et al. Interactions of tumor necrosis factor (TNF) and TNF receptor 
family members in the mouse and human. J. Biol. Chem. 281, 13964–13971 
(2006). 
3. Rodriguez-Barbosa, J. I., Fernandez-Renedo, C., Moral, A. M. B., Buhler, L. & 
Del Rio, M.L. T follicular helper expansion and humoral-mediated rejection are 
inde-pendent of the HVEM/BTLA pathway. Cell Mol. Immunol. 14, 497–510 
(2017). 
4. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to 
CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 (2003). 
5. Bekiaris, V., Sedy, J. R., Macauley, M. G., Rhode-Kurnow, A. & Ware, C. F. The 
inhibitory receptor BTLA controls gammadelta T cell homeostasis and inflam-
matory responses. Immunity 39, 1082–1094 (2013). 
6. Jones, A. et al. Immunomodulatory functions of BTLA and HVEM govern induc-
tion of extrathymic regulatory T cells and tolerance by dendritic cells. Immunity 
45, 1066–1077 (2016). 
7. Maeda, M. et al. Murine CD160, Ig-like receptor on NK cells and NKT cells, 
recognizes classical and nonclassical MHC class I and regulates NK cell 
activation. 
J.Immunol. 175, 4426–4432 (2005). 
8. Murphy, T. L. & Murphy, K. M. Slow down and survive: enigmatic immunor-
egulation by BTLA and HVEM. Annu. Rev. Immunol. 28, 389–411 (2010). 
9. Tu, T. C. et al. CD160 is essential for NK-mediated IFN-gamma production. J. 
Exp. Med. 212, 415–429 (2015). 
10. Hurchla, M. A., Sedy, J. R. & Murphy, K. M. Unexpected role of B and T 
lymphocyte attenuator in sustaining cell survival during chronic allostimulation. 
J. Immunol. 178, 6073–6082 (2007). 
12 
 
11. Giles, D. A. et al. The tumor necrosis factor superfamily members TNFSF14 
(LIGHT), lymphotoxin beta and lymphotoxin beta receptor interact to regulate 
intestinal inflammation. Front. Immunol. 9, 2585 (2018). 
12. Miller, M. L., Sun, Y. & Fu, Y. X. Cutting edge: B and T lymphocyte attenuator 
signalingon NKT cells inhibits cytokine release and tissue injuryin early immune 
responses. J. Immunol. 183,32–36 (2009). 
13. Kim, T.J.P. et al. CD160 serves as a negative regulator of NKT cells in acute 
hepatic injury. Nat. Commun. (2019). 
14. Wang, Y. et al. The role of herpesvirus entry mediator as a negative regulator of 
T cell-mediated responses. J. Clin. Invest. 115, 711–717 (2005). 
15. Giustiniani, J., Marie-Cardine, A. & Bensussan, A. A soluble form of the MHC 
class I-specific CD160 receptor is released from human activated NK 
lymphocytes and inhibits cell-mediated cytotoxicity. J. Immunol. 178, 1293–1300 
(2007). 
